Disc Medicine slips on planned stock sale

Disc Medicine

22/01/2025 13:51

**  Disc Medicine's  IRON.O  shares down 1.9% to $59.35
premarket as biopharma firm looks to raise equity
  
    ** Watertown, Massachusetts-based firm late Tues  $200 mln
offering consisting of stock and pre-funded warrants
  
    ** Co plans to use net offering proceeds to fund research
and clinical development of its product candidates, to support
potential commercialization of its treatment for erythropoietic
protoporphyria (EPP), a 
    rare disease that causes painful sensitivity to light
  
    ** IRON shares on Tues rose nearly 4% to close at $60.52
after co received  from US FDA for 
  
    
      
    
  
    ** Jefferies, Leerink, Stifel and Cantor jt bookrunners for
the equity offering
    
  
    ** Through Tues, IRON shares down 4.5% to begin 2025.
Stock's 1-yr high is $77.60 (Mar 4) and 1-yr low is $25.60 (Apr
1)
  

(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper@tr.com 1-646-279-6380))